Vibronix, a company committed to the research and development of cutting-edge molecular vibration spectroscopy imaging instruments, has recently declared the successful closure of its Series B funding round, raising nearly RMB 100 million. This significant investment was spearheaded by Dongtong Investment, with notable participation from IDG Capital. The newly acquired funds will be strategically allocated to propel the commercialization of Vibronix's products across diverse sectors, including industrial inspection, clinical applications, and the innovative realm of AI for Science.

Established in September 2017, Vibronix has rapidly distinguished itself by developing three proprietary spectroscopic technology platforms, boasting exceptional core performance metrics. The company is at the forefront of embracing the 'AI for Science' paradigm, a testament to its forward-thinking approach. Its products have already made a substantial impact, being deployed across multiple fields and successfully delivered to numerous research institutions and enterprises, both within China and on the global stage.

Prior to this, Vibronix had already secured two rounds of funding, laying a solid foundation for its growth. The CEO of Vibronix expressed confidence that this latest infusion of capital will catalyze a commercial leapfrog in three pivotal directions. Looking ahead, the company remains steadfast in its commitment to technological innovation, aiming to craft high-end, domestically produced scientific instruments. Moreover, Vibronix is dedicated to fostering intelligent transformation and import substitution within the industry, thereby contributing to China's scientific and technological self-reliance.